InvestorsHub Logo
Followers 5
Posts 475
Boards Moderated 0
Alias Born 09/27/2012

Re: Protector post# 191804

Friday, 09/26/2014 4:45:03 PM

Friday, September 26, 2014 4:45:03 PM

Post# of 346282
SK wasn't as precise as I would have preferred on the time frame, but FY is a reasonable interpretation. But whether he meant this calendar year, or this FY, he was perfectly clear in "partnerships" plural, and that they would be brought to fruition.

From the March 7, 2014 earnings call...

While specifics cannot be discussed until deals are culminated, what I can say is that we have seen a high level of interest from potential partners in the bavituximab program as a whole, in collaborating with us to evaluate bavituximab in combination with other novel immunotherapies, in collaborating with us on new areas and in our contract manufacturing services.

With the Phase III study now underway, our main interest in partnering for the bavituximab program would be to allow us to be more aggressive in advancing new clinical indications, namely moving new indications in the later-stage development in areas such as breast and liver cancer. And we look forward to updating you as partnerships are brought to fruition over the coming year.




Add to that the statements of SK that they want to bring partnerships to fruition and this in the current FY..

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News